Respiratory Disorders
Conditions
Keywords
healthy volunteer, TNFR1, domain antibody, Lung injury
Brief summary
This will be a 3 part study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of GSK2862277 administered via inhalation (IH) or intravenous (IV) routes in healthy subjects. Part 1 of this study will involve an initial assessment of safety, tolerability and pharmacokinetics of GSK286227, via single escalating intravenous doses, compared to a predecessor molecule, GSK1995057. After completion of Part 1 an interim data review will occur which will assess key comparability criteria to inform progression to Part 2 of the study. Part 2 of the study will involve single doses of GSK2862277 at a level predicted to be at or close to therapeutic dose levels. Part 2 will investigate both intravenous and inhaled routes of administration, in sequential manner, respectively. An interim data review will also occur after completion of Part 2, where all data accumulated previously will be assessed to examine appropriateness to progress to Part 3. Part 3 of the study will involve 5 days of repeat dosing via both inhaled and intravenous routes using the same dose administered in Part 2.
Interventions
DRUGSingle IV dose of GSK2862277
GSK2862277 solution available in a 40 mg vial for IV administration.
DRUGMatching placebo single dose IV infusion
Matching placebo solution available for IV administration.
DRUGSingle IH dose of GSK2862277
GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
DRUGMatching placebo single dose IH
Matching placebo nebulised solution available for IH administration.
DRUGRepeat IV dose of GSK2862277
GSK2862277 solution available in a 40 mg vial for IV administration.
DRUGMatching placebo repeat dose IV infusion
Matching placebo solution available for IV administration.
DRUGRepeat IH dose selected of GSK2862277 from Part 2
GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
DRUGMatching placebo repeat dose IH
Matching placebo nebulised solution available for IH administration.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent. * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. * Subject is positive at screening for HAVH autoantibodies against GSK1995057 (Part 1 only). * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening * A positive pre-study drug/alcohol screen. * A positive test for human immunodeficiency virus (HIV) antibody. * Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Exclusion criteria
* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening * A positive pre-study drug/alcohol screen. * A positive test for human immunodeficiency virus (HIV) antibody. * Exposure to more than four new chemical entities within 12 months prior to the first dosing day
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity in subjects receiving repeat IV or IH dose of GSK2862277 in Part 3 | Up to 60 days | Presence of anti GSK2862277 binding antibodies will be evaluated. |
| Safety and tolerability of single IV or IH dose of GSK2862277 assessed by vital signs in Part 1 and Part 2 | Up to 42 days | Vital signs will include blood pressure (BP), heart rate respiration rate and body temperature. |
| Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by vital signs in Part 3 | Up to 42 days | Vital signs will include BP, heart rate respiration rate and body temperature. |
| Safety and tolerability of single IV or IH dose of GSK2862277 assessed by ECG in Part 1 and Part 2 | Up to 42 days | Safety data will include electrocardiogram (ECG) readings obtained at each timepoint during the study. |
| Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by ECG in Part 3 | Up to 42 days | Safety data will include ECG readings obtained at each timepoint during the study. |
| Safety and tolerability of single IV or IH dose of GSK2862277 assessed by spirometry monitoring in Part 1 and Part 2 | Up to 42 days | Spirometry monitoring will include forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). |
| Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by spirometry monitoring in Part 3 | Up to 42 days | Spirometry monitoring will include FEV1 and FVC. |
| Safety and tolerability of single IV dose of GSK2862277 as assessed by measurement of plasma cytokines in Part 1 | Up to 42 days | Blood samples will be collected for assessment of plasma cytokines. |
| Immunogenicity in subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2 | Up to 60 days | Presence of anti GSK2862277 binding antibodies will be evaluated. |
| Safety and tolerability of single IV or IH dose of GSK2862277 assessed by number of subjects with adverse events (AE)s in Part 1 and Part 2 | Up to 42 days | Safety and tolerability parameters will include recording of adverse events (AEs), throughout the study. |
| Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by number of subjects with AEs in Part 3 | Up to 42 days | Safety and tolerability parameters will include recording of AEs, throughout the study. |
| Safety and tolerability of single IV or IH dose of GSK2862277 assessed by laboratory tests in Part 1 and Part 2 | Up to 42 days | Laboratory tests will include haemogram, clinical chemistry, urine examination. |
| Safety and tolerability of repeat IV or IH dose of GSK2862277 as assessed by laboratory tests in Part 3 | Up to 42 days | Laboratory tests will include haemogram, clinical chemistry, urine examination. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters in subjects receiving repeat IV dose of GSK2862277 in Part 3 Cohort 3a | Up to 48 hours post last dose | The blood samples will be collected for plasma concentrations of GSK2862277. |
| PK parameters in subjects receiving repeat IH dose of GSK2862277 in Part 3 Cohort 3b | Up to 48 hours post last dose | The blood samples will be collected for plasma concentrations of GSK2862277 |
| PK parameters in subjects receiving single IV dose of GSK2862277 in Part 1 | Up to 48 hours post last dose | The PK parameters will be compared with historic GSK1995057 PK data in Part 1 |
| Pharmacodynamic and immune function biomarkers in serum of subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2 | Up to 48 hours post last dose | The pharmacodynamic and immune function biomarkers in serum. |
| Pharmacodynamic and immune function biomarkers in serum of subjects receiving repeat IV or IH dose of GSK2862277in Part 3 | Up to 48 hours post last dose | The pharmacodynamic and immune function biomarkers in serum. |
| Change from baseline in IL-8 expression in ex vivo WBA in subjects receiving single IV 0.05 mg/kg dose of GSK2862277 in Part 1 in Cohort1c | Up to 12 hours post dose | IL-8 expression in ex vivo whole blood essay (WBA). |
| Composite of urine parameters in subjects receiving single IV 2 mg/kg dose of GSK2862277 in Part 2 in Cohort 2a | Up to 48 hours post dose | The urine samples will be collected for urine concentrations of GSK2862277. |
| Pharmacokinetic (PK) parameters in subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2 | Up to 48 hours post dose | The blood samples will be collected for plasma concentrations of GSK2862277. |
Countries
United Kingdom
Outcome results
None listed